Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.48 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392324 | 0.95 | KEAP1 (0.51) | CALCRLOPRM1OPRD1RAMP1KEAP1 | |
| SCHEMBL29392539 | 0.94 | CALCRL (0.56) | CALCRLOPRM1OPRD1RAMP1KEAP1 | |
| SCHEMBL29392890 | 0.93 | CALCRL (0.56) | CALCRLOPRM1OPRD1RAMP1KEAP1 | |
| SCHEMBL29392282 | 0.90 | CALCRL (0.58) | CALCRLOPRM1OPRD1RAMP1 | |
| SCHEMBL29392795 | 0.89 | CALCRL (0.55) | CALCRLOPRM1OPRD1RAMP1KEAP1 | |
| SCHEMBL29392901 | 0.88 | EPHA2 (0.57) | CALCRLRAMP1KEAP1NMUR2NMUR1 | |
| SCHEMBL30443604 | 0.86 | NMUR2 (0.55) | CALCRLOPRM1OPRD1RAMP1KEAP1 | |
| SCHEMBL30186430 | 0.85 | CALCRL (0.61) | CALCRLOPRM1OPRD1RAMP1 | |
| SCHEMBL6887928 | 0.85 | OPRD1 (0.55) | OPRM1OPRD1 | |
| SCHEMBL6887945 | 0.85 | OPRD1 (0.55) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165943-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | CHRYSALIS BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4132948-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | Chrysalis Biotherapeutics (US) | 2023-02-15 | — | — | EP | disclosed |